
    
      Part 1 of the study will first evaluate the safety and tolerability of ZW25 in combination
      with palbociclib plus fulvestrant and will confirm the recommended doses (RDs) of ZW25 and
      palbociclib in this combination. Part 2 of the study will evaluate the anti-tumor activity of
      the combination of ZW25 with palbociclib plus fulvestrant at the RD level in patients with
      HER2-positive, HR-positive advanced breast cancer.
    
  